The European Medicines Agency's Committee for Advanced Therapies (CAT) has laid out its Work Plan for 2026, aiming to refine oversight and development paths for advanced therapies including gene and cell treatments. This detailed blueprint primarily targets pharma companies pioneering advanced therapies, national regulatory bodies, healthcare providers, and patients relying on innovative medical solutions, marking a fertile ground for engagement and ongoing debates about regulatory rigor and innovation facilitation.
Published on February 4, 2026, by the EMA, this document serves as the CAT’s roadmap for addressing the emerging challenges and opportunities within the fast-evolving field of advanced therapies. The CAT operates as a specialized committee inside the EMA, tasked with scientific evaluation and regulatory advice specifically for advanced therapy medicinal products (ATMPs).
This is a strategic work plan document, not legislation, outlining key priorities and action points for the year ahead. It sets clear operational goals with deadlines and specific areas for improvement, such as enhanced collaboration with stakeholders, improved regulatory guidance for ATMP developers, and streamlined evaluation procedures. However, it stops short of introducing binding legislative changes or fixed numerical targets.
The plan pushes for increased regulatory clarity and adaptive frameworks to accelerate the approval and availability of innovative therapies. It leans towards strengthening EMA’s supervisory role and deepening cooperation with national authorities to maintain safety standards while encouraging innovation. This reflects a tilt towards tighter oversight in a complex, cutting-edge sector, balanced against the needs of speedy patient access.
Pharmaceutical developers and biotech firms stand to benefit from clearer pathways and potentially faster approvals, although they may also face more rigorous evidence requirements and ongoing regulatory scrutiny. National regulators might experience additional coordination duties but gain stronger support from EMA’s central role. Patients could enjoy quicker access to novel treatments but might confront higher costs or uncertainties inherent to advanced therapies. Healthcare providers will need to adapt to evolving treatment standards and regulatory expectations.
This work plan signals the start of EMA’s focused agenda for 2026 in advanced therapies regulation. It is expected to be followed by inputs from national competent authorities and continued engagement with industry stakeholders to translate these orientations into concrete actions and possible regulatory refinements.